pharmacologic therapy in heart disease rafael mena md december 3 rd 2010
TRANSCRIPT
![Page 1: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/1.jpg)
Pharmacologic Therapy in Heart Disease
Rafael Mena MDDecember 3rd 2010
![Page 2: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/2.jpg)
Cardiac Medications of Interest in NICU
• Inotropes and vasopressors• Prostaglandins• Antihypertensives• Diuretics context CHF
![Page 3: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/3.jpg)
MAP
• Cardiac Output X SVR
![Page 4: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/4.jpg)
Inotropes and Vasopressors
• Epinephrine• Milrinone• Hydrocortisone
![Page 5: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/5.jpg)
Hypotension
• Difficult to define and measure• MAP and Gestational age• Consensus end organ damage not beneficial• ? Treatment decreases mortality and adverse
long-term outcomes
![Page 6: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/6.jpg)
Current definitions of hypotension do not predict abnormal HUS findings in preemies
• Measured Hypotension 84 infants <30wks via UAC’s in first 72 hours
• 3 definitions of hypotension• HUS lesions were not predicted by any of the
definitions or MAP variability• Blood pressure management alone might not
prevent injury
Limperopouloset al Pediatrics November 2007
![Page 7: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/7.jpg)
Early systemic hypotension and vasopressors in LBW: Impact Neurodevelopment
• Prospective study evaluating effect on neurodevelopment with inotropes in LBWI
• 130 infants. Half treated with Epinephrine and Dopamine. The rest control group
• Outcome measures: Cranial US and neurodevelopment at 2 years
• No differences between groups in neurodevelopment and developmental delay
• Inotropes seem be safe
Pellicer et al, Pediatrics May 2009
![Page 8: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/8.jpg)
Epinephrine and others
Courtesy Beth Ann Johnson
![Page 9: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/9.jpg)
G proteins
![Page 10: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/10.jpg)
Epinephrine vs. Dopamine in LBWI
• Prospective RCT in 60 newborns <1500g. Dopamine dose 2-10ug/kg. Epinephrine 0.1 to 0.5 ug/kg
• Similar effectiveness in raising BP• Epinephrine more hyperglycemia and increase
lactate (Beta stimulation not hypoperfusion)• No difference PDA,BPD,NEC,ROP• Epinephrine could be used first line
Valverde et al, Pediatrics May 2006
![Page 11: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/11.jpg)
Previous studies
• Have reported a decrease in cardiac performance with dopamine
• Higher doses,>10 ug/kg might lead to increase in SVR and leading to myocardial depression
• Different Dopamine studies prefer 2-10 ug/kg dose in preterm infants with impaired CV function
![Page 12: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/12.jpg)
Milrinone
• Inhibitor of phosphodiesterase III (cardiac and vascular tissues)
• In cardiac muscle, CAMP, potentiates Calcium delivery (Inotrope)
• Vascular smooth muscle, CAMP produces relaxation( decrease SVR)
![Page 13: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/13.jpg)
Afterload Reducer
• LV afterload reduction due to decrease in total peripheral resistance and a resulting increase in CO
• Decreases PVR resulting in biventricular afterload reduction
![Page 14: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/14.jpg)
Side effects
• Hypotension• Thrombocytopenia• Arrythmias
![Page 15: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/15.jpg)
Efficacy and safety of milrinone in preventing LCOS in infants and children after corrective surgery for CHD
• PRIMACORP study• Prophylactic Intravenous Use of Milrinone
After Cardiac Operation in Pediatrics• Circulation 2003
![Page 16: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/16.jpg)
PRIMACORP study
• Evaluate the safety and efficacy of prophylactic Milrinone in pediatric patients at high risk of developing LOCS
• Multicenter(31), randomized, double blind, placebo controlled
![Page 17: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/17.jpg)
Results
Hoffman et al, Circulation 2003
![Page 18: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/18.jpg)
PRIMACORP study
• The results show a 64% relative risk reduction in the development of LOCS with the prophylactic use of high dose milrinone
• High dose milrinone: 75 ug/kg bolus, followed by a 0.75 ug/kg/min infusion for 35 hrs
![Page 19: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/19.jpg)
Milrinone improves oxygenation in newborns with severe PPHN
• Many neonates with severe PPHN are poor responders to NO
• 9 full term infants with severe PPHN, OI>20, failure of INO therapy, ECHO confirmation received Milrinone median 70 hrs
• OI marked better especially first 24 hrs• No systemic hypotension
Mcnamara et al, Journal of Critical Care 2006
![Page 20: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/20.jpg)
Hydrocortisone
• Preemies can have a transient adrenal insufficiency
• Improves cardiovascular stability• Dexamethasone impairs neurodevelopment,
does hydrocortisone?
![Page 21: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/21.jpg)
RCT of a stress dose of Hydrocortisone for refractory hypotension in premature infants
• Assess effectiveness of a hydrocortisone stress dose in infants with refractory hypotension
• Prospective RCT of 48 infants with hypotension
• 24 had Dopamine + Hydrocortisone• 24 had Dopamine + placebo• Stress dose hydrocortisone dose 1mg/kg every
8 hrs 5 days
Ng et al, Pediatrics 2006
![Page 22: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/22.jpg)
Hydrocortisone for refractory hypotension works
• Hydrocortisone group weaned vasopressor support faster
• 2 in HC group vs. 11 infants in placebo group required an additional vasopressor
• Preferable than Dexamethasone, but caution
![Page 23: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/23.jpg)
• Prostaglandins
![Page 24: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/24.jpg)
When Prostaglandins are not enough: Lesions likely to require urgent intervention after delivery
• HLH with intact atrial septum• TGA with restrictive ASD• TAPVR with obstruction• TOF with absent pulmonary valve
![Page 25: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/25.jpg)
Hypoplastic Left Heart with intact
atrial septum
1) Hypoplastic ascending aorta and aortic arch
2) Hypoplastic Left Ventricle3) Large PDA supplying the
only source of blood flow to the body
4) ASD allowing blood return from the lungs to reach single ventricle
![Page 26: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/26.jpg)
Transposition Great Arteries with restrictive ASD
1) Aorta arising from the RV(poor Oxygenated blood body)
2) Pulmonary artery arising from LV(well oxygenated blood back to lungs)
![Page 27: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/27.jpg)
Total Anomalous Pulmonary Venous Return with Obstruction
Supracardiac Infracardiac
Blood return to SVC Blood Return to Hepatic Veins, then IVC. Most common type to be Obstructed
![Page 28: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/28.jpg)
Tetralogy of Fallot with absent Pulmonary Valve
1) Severely dilated main and branch pulmonary arteries causing external bronchial compression
![Page 29: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/29.jpg)
Examples of ductal dependent lesions
• Left sided lesions-Coarctation of Aorta-Critical Aortic Stenosis• Right sided lesions- Tricuspid/Pulmonary Atresia• TGA
![Page 30: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/30.jpg)
Neoreview Question• You are reviewing the records of a 5-month-old African American female
infant in the neonatal intensive care unit. She was delivered at 36 weeks' gestation with an antenatal diagnosis of truncus arteriosus and interrupted aortic arch. Postnatal echocardiography confirmed the antenatal findings and revealed ductus-dependent coronary circulation. The infant has been receiving alprostadil infusion since birth and is awaiting heart transplantation. She was also diagnosed to have Di George syndrome with hypoparathyroidism and immunodeficiency, and is receiving calcitriol, calcium glubionate, and bactrim prophylaxis. She is receiving decongestive therapy with furosemide and aldactone. She is also receiving metoclopramide for gastroesophageal reflux. The resident physician reports firm swelling of both forearms without any tenderness, erythema, fluctuation, or signs of inflammation. Complete blood count measurement taken the same day shows normal findings for age. You request radiography of the forearms.
![Page 31: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/31.jpg)
Describe Figure
![Page 32: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/32.jpg)
Hyperostosis
• Long treatment(>40 days)• Clavicle is most frequent site• No long term problems with bone growth
once stopped
![Page 33: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/33.jpg)
Other complications
• Fever• Hypotension• Apnea
![Page 34: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/34.jpg)
• Drugs for neonatal hypertension
![Page 35: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/35.jpg)
Sounds familiar?
• An ex 24 wk now 37 wks old is on full feeds and ready to go home. You are rounding and the nurse brings to your attention that his systolic pressures have been >110 for the past 3 days. Work up including renal labs and US, urine Ca to creatinine ratio is normal. What are your therapeutic choices?
![Page 36: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/36.jpg)
Systemic hypertension in VLBW infants with BPD
• Purpose: determine if systemic HTN occurred in VLBW with BPD
• 73 patients in their cohort , which 41 had BPD and 12% of them had HTN
• The hypertensive infants all had BPD and longer hospital stay
• Infants with severe BPD risk of hypertension
Alagappan et al, Am J Perinatol 1998
![Page 37: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/37.jpg)
Age specific percentiles of blood pressure measurement (n=13,000 infants)
Age in months Systolic BP’s 95% Systolic BP’s 50%
1 108 85
2 108 85
3 110 90
4 110 90
Report of the Second Task Force of Blood Pressure Control in Children
![Page 38: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/38.jpg)
Important tests in Neonatal Hypertension
• Renal panel• Calcium• Renal US with Doppler
![Page 39: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/39.jpg)
Useful Oral Agents
Drug Class Dose Comments
Captopril ACE inhbitor From 0.01mg/kg up to 6mg/kg
CommonMonitor K and creatinine
Amlodipine Channel blocker From 0.1 to 0.6 mg/kg
Being used more often
Hydrochlorothiazide Thiazide 20-40mg/kg/day Monitor electrolytes
Flynn, Pediatric Nephrology 2000
![Page 40: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/40.jpg)
Mechanism of Action
Drug Mechanism of Action
Ace Inhibitors Blocks angiotensin converting enzyme, thus decrease in Angiotensin 2 leading to vasodilation and less salt retention
Calcium Channel Blockers Relaxation of vascular smooth muscle
Thiazide diuretics Inhibits Na in the distal tubule, natriuresis
![Page 41: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/41.jpg)
• Diuretics in context of Heart Failure
![Page 42: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/42.jpg)
Recent UC case
3 wk old former 37 weeker with Trisomy 21 with known AV canal. Initially taking almost 80% PO. As weeks progressed, she got more tachypneic, was barely taking PO and had hepatomegaly on physical exam. Started on Lasix, Aldactone and afterwards in Captopril.
![Page 43: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/43.jpg)
Diuretics
• Lasix works in loop of Henle and is has strong Natriuresis
• Aldactone weak diuretic and potassium sparing
• Alleviate pulmonary edema and overcirculation seen in heart failure
![Page 44: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/44.jpg)
Spironolactone therapy in infants with CHF secondary to CHD
• Studied the efficacy of spironolactone on heart failure in 21 patients under 1 year
• All received Digoxin and Chlorothiazide• 10 without vs. 11 with Aldactone• Improved hepatomegaly and reduction in
weight• Addition of Aldactone can improve symptoms
in heart failure patientsHobbins, Archive of Disease in Childhood 1981
![Page 45: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/45.jpg)
?????????????????
• Thanks
![Page 46: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/46.jpg)
References1) Pellicer et al,Early systemic hypotension and vasopressor support in
LBWI: Impact on Neurodevelopment, Pediatrics 2009 123:13692) Limperoupoulos et al, Current definitions of hypotension do not predict
abnormal cranial US finding in preterm infants, Pediatrics Nov 2007;120, 966-977
3) Valverde et al, Dopamine vs. Epinephrine for cardiovascular support in LBWI: Analysis of systemics effect and neonatal clinical outcomes, Pediatrics 2007;117, 1213-1222
4) Hoffman et al, Efficacy and Safety of Milrinone in preventing low cardiac output syndrome in infants and children after corrective surgery for congenital heart disease, Circulation 2003;107:996-1002
5) Mcnamara et al, Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn, Journal of Critical Care 2006;21:217-223
![Page 47: Pharmacologic Therapy in Heart Disease Rafael Mena MD December 3 rd 2010](https://reader031.vdocument.in/reader031/viewer/2022032604/56649e635503460f94b5fdf5/html5/thumbnails/47.jpg)
5) Ng et al, A double blind Randomized controlled study of a dose of Hydrocortisone for Rescue treatment of refractory hypotension in preterm infants, Pediatrics:110, February 2006
6) Alagappan et al, Systemic hypertension in VLBW with BPD: incidence and risk factors. Am J Perinatol Jan 1998;15(1) 3-8
7) Flynn, Neonatal Hypertension : Diagnosis and Management, Pediatric Nephrology 2000 14:332-341
8) Hobbins et al, Spironolactone therapy in infants with congestive heart failure secondary to congenital heart disease, Archives of Disease in Childhood, 1981, 56:934-938